21 results on '"Richou, Carine"'
Search Results
2. Alveolar echinococcosis in solid organ transplant recipients: a case series from two national cohorts
- Author
-
Marquis Bastian, Demonmerot Florent, Richou Carine, Thiéfin Gérard, Millon Laurence, Wallon Martine, Vuitton Dominique Angèle, Grall-Jezequel Anne, Grenouillet Frédéric, Epaulard Olivier, Gervais Philippe, Manuel Oriol, and Bresson-Hadni Solange
- Subjects
solid-organ transplant ,alveolar echinococcosis ,echinococcus multilocularis ,immunosuppression ,Infectious and parasitic diseases ,RC109-216 - Abstract
Alveolar echinococcosis (AE) is a severe parasitic infection caused by the ingestion of Echinococcus multilocularis eggs. While higher incidence and faster evolution have been reported in immunosuppressed patients, no studies have been performed specifically on AE in transplant patients. We searched for all de novo AE cases diagnosed between January 2008 and August 2018 in solid organ transplant (SOT) recipients included in the Swiss Transplant Cohort Study and the FrancEchino Registry. Eight cases were identified (kidney = 5, lung = 2, heart = 1, liver = 0), half of which were asymptomatic at diagnosis. AE diagnosis was difficult due to the low sensitivity (60%) of the standard screening serology (Em2+) and the frequently atypical radiological presentations. Conversely, Echinococcus Western blot retained good diagnostic performances and was positive in all eight cases. Five patients underwent surgery, but complete resection could only be achieved in one case. Moreover, two patients died of peri-operative complications. Albendazole was initiated in seven patients and was well tolerated. Overall, AE regressed in one, stabilized in three, and progressed in one case, and had an overall mortality of 37.5% (3/8 patients). Our data suggest that AE has a higher mortality and a faster clinical course in SOT recipients; they also suggest that the parasitic disease might be due to the reactivation of latent microscopic liver lesions through immune suppression. Western blot serology should be preferred in this population. Finally, surgery should be considered with caution, because of its low success rate and high mortality, and conservative treatment with albendazole is well tolerated.
- Published
- 2023
- Full Text
- View/download PDF
3. Molecular diagnosis of alveolar echinococcosis in patients based on frozen and formalin-fixed paraffin-embedded tissue samples
- Author
-
Knapp Jenny, Lallemand Séverine, Monnien Franck, Felix Sophie, Valmary-Degano Séverine, Courquet Sandra, Demonmerot Florent, Heyd Bruno, Turco Celia, Doussot Alexandre, Bourgeois Lucie, Bresson-Hadni Solange, Richou Carine, and Millon Laurence
- Subjects
echinococcus multilocularis ,molecular diagnosis ,fresh material ,ffpe ,end-point pcr ,qpcr ,Infectious and parasitic diseases ,RC109-216 - Abstract
Confirmed diagnosis of alveolar echinococcosis (AE) is based on pathological criteria and molecular evidence. This parasite-borne disease, caused by the cestode Echinococcus multilocularis, sparingly involves humans as a dead-end host. In humans, the parasite mainly colonizes the liver but can colonize any organ and cause atypical forms, often difficult to characterize clinically. Moreover, molecular methods may be suitable to make the diagnosis of AE in cases of atypical forms, extra-hepatic localizations, or immunosuppressed patients. The aim of this study was to determine the most relevant published PCR techniques, for diagnosis of AE in patients and adopt the best strategy for molecular diagnosis depending on the nature of the tested sample. In this study, we evaluated nine end-point PCR assays and one real-time PCR assay (qPCR), targeting mitochondrial genes, using a total of 89 frozen or formalin-fixed paraffin-embedded (FFPE) samples from either 48 AE or 9 cystic echinococcosis patients. Targeted fragment-genes ranged from 84 to 529 bp. Six PCR assays were able to amplify the DNA of 100% of the frozen AE-samples and for one PCR, 69.8% of the FFPE AE-samples. The 16S rrnL PCR (84 bp) was positive in PCR for 77% of the AE samples and in qPCR for 86.5%. The sensitivity of the PCR assays was higher for fresh samples and FFPE samples stored for less than 5 years. The qPCR assay further increased sensitivity for the tested samples, confirming the need for the development of an Echinococcus spp. qPCR to improve the molecular diagnosis of echinococcoses.
- Published
- 2022
- Full Text
- View/download PDF
4. Prognosis of cirrhotic patients admitted to intensive care unit: a meta-analysis
- Author
-
Weil, Delphine, Levesque, Eric, McPhail, Marc, Cavallazzi, Rodrigo, Theocharidou, Eleni, Cholongitas, Evangelos, Galbois, Arnaud, Pan, Heng Chih, Karvellas, Constantine J., Sauneuf, Bertrand, Robert, René, Fichet, Jérome, Piton, Gaël, Thevenot, Thierry, Capellier, Gilles, Di Martino, Vincent, Di Martino, Vincent, Weil, Delphine, Thévenot, Thierry, Cervoni, Jean-Paul, Richou, Carine, Vanlemmens, Claire, Dritsas, Stavros, Capellier, Gilles, Piton, Gaël, Chaignat, Claire, Pili-Floury, Sébastien, Blasco, Gilles, Samain, Emmanuel, Samuel, Didier, Levesque, Eric, Saliba, Faouzi, Ichaï, Philippe, Galbois, Arnaud, Guidet, Bertrand, Das, Vincent, Sauneuf, Bertrand, Mira, Jean-Paul, Perrotin, Dominique, Champigneulle, Benoit, Pene, Frédéric, Robert, René, Filloux, Bruno, Silvain, Christine, Fichet, Jérome, McPhail, Marc, Wendon, Julia, Shawcross, Debbie, Bernal, William, Theocharidou, Eleni, Agarwal, Banwari, Burroughs†, Andrew K., Cholongitas, Evangelos, Cavallazzi, Rodrigo, Karvellas, Constantine J., Pan, Heng Chih, Chen, Yung-Chang, Tsai, Ming-Hung, and METAREACIR Group
- Published
- 2017
- Full Text
- View/download PDF
5. Systematic screening for advanced liver fibrosis in patients with coronary artery disease: The CORONASH study
- Author
-
Thévenot, Thierry, primary, Vendeville, Sophie, additional, Weil, Delphine, additional, Akkouche, Linda, additional, Calame, Paul, additional, Canivet, Clémence M., additional, Vanlemmens, Claire, additional, Richou, Carine, additional, Cervoni, Jean-Paul, additional, Seronde, Marie-France, additional, Di Martino, Vincent, additional, and Boursier, Jérôme, additional
- Published
- 2022
- Full Text
- View/download PDF
6. Prognostic value of C-reactive protein levels in patients with cirrhosis
- Author
-
Di Martino, Vincent, Coutris, Caroline, Cervoni, Jean-Paul, Dritsas, Stavros, Weil, Delphine, Richou, Carine, Vanlemmens, Claire, and Thevenot, Thierry
- Published
- 2015
- Full Text
- View/download PDF
7. Phylogenetic inference of Echinococcus multilocularis by whole mitochondrial sequencing.
- Author
-
Lallemand, Severine, Oyhenart, Jorge, Valot, Benoit, Borne, Romain, Bohard, Louis, Umhang, Gerald, Karamon, Jacek, Konyaev, Sergey, Ronnberg, Caroline, Gottstein, Bruno, Weil-Verhoeven, Delphine, Richou, Carine, Bresson-Hadni, Solange, Millon, Laurence, Clerget, Anne Pauline Bellanger, and Knapp, Jenny
- Published
- 2024
8. Fatty acid composition of the erythrocyte membrane and risk of hepatocellular carcinoma in cirrhotic patients
- Author
-
Mouillot, Thomas, Rizk, Maud, Pais de Barros, Jean-Paul, Gilloteau, Adrien, Busson, Amandine, Bernard-Chabert, Brigitte, Thiefin, Gérard, Barraud, Hélène, Bronowicki, Jean-Pierre, Richou, Carine, Di Martino, Vincent, Doffoel, Michel, Minello, Anne, Latournerie, Marianne, Jouve, Jean-Louis, Brondel, Laurent, Brindisi, Marie-Claude, Petit, Jean-Michel, Hillon, Patrick, Cottet, Vanessa, Group, for the CiRCE Study, Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Centre des Sciences du Goût et de l'Alimentation [Dijon] (CSGA), Université de Bourgogne (UB)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Centre National de la Recherche Scientifique (CNRS)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Lipides - Nutrition - Cancer [Dijon - U1231] (LNC), Université de Bourgogne (UB)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre d'Investigation Clinique 1432 (Dijon) - Epidemiologie Clinique/Essais Cliniques (CIC-EC), Université de Bourgogne (UB)-Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon)-Institut National de la Santé et de la Recherche Médicale (INSERM), Laboratoire d'Excellence : Lipoprotéines et Santé : prévention et Traitement des maladies Inflammatoires et du Cancer (LabEx LipSTIC), École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut Gustave Roussy (IGR)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Université de Bourgogne (UB)-Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon)-Centre Régional de Lutte contre le cancer Georges-François Leclerc [Dijon] (UNICANCER/CRLCC-CGFL), UNICANCER-UNICANCER-Institut National de la Santé et de la Recherche Médicale (INSERM)-Fédération Francophone de la Cancérologie Digestive, FFCD-Université de Montpellier (UM)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté])-Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Université Bourgogne Franche-Comté [COMUE] (UBFC), Centre Hospitalier Universitaire de Reims (CHU Reims), Service d'Hépato-gastro-entérologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), CHU Strasbourg, Centre National de la Recherche Scientifique (CNRS), CHU Metz, UFR des Sciences de Santé (Université de Bourgogne), Université de Bourgogne (UB), Cancéropôle du Grand-Est (CGE), Ligue Nationale contre le Cancer, Fondation de France, Canceropole Grand-Est, European Regional Development Fund, Agence Nationale de la Recherche, Institut National du Cancer, Conseil Régional de Bourgogne-Franche-Comté, and ANR-11-LABX-0021,Lipstic,Lipoprotéines et santé : prévention et traitement des maladies inflammatoires non vasculaires et du(2011)
- Subjects
Liver Cirrhosis ,Male ,medicine.medical_specialty ,Carcinoma, Hepatocellular ,Cirrhosis ,Endogeny ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,Gastroenterology ,03 medical and health sciences ,0302 clinical medicine ,Risk Factors ,Internal medicine ,Odds Ratio ,medicine ,Carcinoma ,Humans ,Pharmacology (medical) ,Phospholipids ,Aged ,030304 developmental biology ,chemistry.chemical_classification ,0303 health sciences ,Hepatology ,business.industry ,Erythrocyte Membrane ,Fatty Acids ,Liver Neoplasms ,Case-control study ,Fatty acid ,Odds ratio ,Metabolism ,Middle Aged ,[SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism ,medicine.disease ,digestive system diseases ,3. Good health ,chemistry ,Case-Control Studies ,030220 oncology & carcinogenesis ,Hepatocellular carcinoma ,Female ,business ,[SDV.AEN]Life Sciences [q-bio]/Food and Nutrition ,Biomarkers - Abstract
International audience; BACKGROUND: Disturbances in fatty acid (FA) metabolism have been reported in cirrhosis, but the role of FAs in the development of hepatocellular carcinoma (HCC) is still unclear. Biomarkers are a promising means to explore the associations between exogenous intake or endogenous production of FAs and cancer risk. AIMS: To estimate the relationship between fatty acid content in erythrocyte membranes and HCC risk in cirrhotic patients. METHODS: The "CiRCE" case-control study recruited cirrhotic patients from six French hospitals between 2008 and 2012. Cases were cirrhotic patients with HCC (n = 349); controls were cirrhotic patients without HCC at inclusion (n = 550). FA composition of phospholipids in erythrocyte membranes was determined by high performance gas chromatography. Odds ratios for HCC risk according to FA concentrations were estimated with multivariable logistic regression. RESULTS: HCC patients were older and more often men (P
- Published
- 2020
- Full Text
- View/download PDF
9. Should Possible Recurrence of Disease Contraindicate Liver Transplantation in Patients with End-Stage Alveolar Echinococcosis? a 20-Year Follow-Up Study
- Author
-
Bresson-Hadni, Solange, Blagosklonov, Oleg, Knapp, Jenny, Grenouillet, Frédéric, Sako, Yasuhito, Delabrousse, Eric, Brientini, Marie-Pascale, Richou, Carine, Minello, Anne, Antonino, Anca-Teodora, Gillet, Michel, Ito, Akira, Mantion, Georges André, and Vuitton, Dominique Angèle
- Published
- 2011
- Full Text
- View/download PDF
10. Genotyping Echinococcus multilocularis in Human Alveolar Echinococcosis Patients: An EmsB Microsatellite Analysis
- Author
-
Knapp, Jenny, primary, Gottstein, Bruno, additional, Bretagne, Stéphane, additional, Bart, Jean-Mathieu, additional, Umhang, Gérald, additional, Richou, Carine, additional, Bresson-Hadni, Solange, additional, and Millon, Laurence, additional
- Published
- 2020
- Full Text
- View/download PDF
11. Comparison of the serological tests ICT and ELISA for the diagnosis of alveolar echinococcosis in France☆
- Author
-
Knapp Jenny, Sako Yasuhito, Grenouillet Frédéric, Bresson-Hadni Solange, Richou Carine, Gbaguidi-Haore Houssein, Ito Akira, and Millon Laurence
- Subjects
alveolar echinococcosis ,diagnosis ,rEm18 ,immunochromatography ,rapid test ,rEm18-ELISA and Em2-Em18-ELISA tests ,Infectious and parasitic diseases ,RC109-216 - Abstract
Serological diagnosis of alveolar echinococcosis (AE) is a key element for efficient patient treatment management. A rapid immunochromatography test kit (ICT) using the recombinant Em18 antigen (rEm18) was recently developed. The aim of our study was to assess this test on a panel of sera from French patients with alveolar echinococcosis and control patients. In a blind test, a total of 112 serum samples were tested including samples of AE (n = 30), cystic echinococcosis [CE] (n = 15), and polycystic echinococcosis [PE] (n = 1). For the comparison, 66 sera from patients with hepatocarcinoma, fascioliasis, toxocariasis, Caroli’s disease, or autoimmune chronic active hepatitis were used. The diagnostic test sets we used were the rEm18-ICT and two validated ELISAs with rEm18 and Em2-Em18 antigens, respectively. For the ICT, 27/30 sera from AE patients, 4/15 sera from CE patients and the PE patient serum were positive. One serum from the control panel (toxocariasis) was positive for the ICT. The rEm18-ICT sensitivity (90.0%) and specificity (92.7%) for detection of Em18-specific antibodies confirmed it as a relevant tool for AE diagnosis. The rEm18-ELISA had a sensitivity of 86.7% and specificity of 91.5%, and the Em2-Em18-ELISA had a sensitivity of 96.7% and specificity of 87.8%. However, when AE patient sera are recorded as weak in intensity with the ICT, we recommend a double reading and use of a reference sample if the ICT is used for patient follow-up.
- Published
- 2014
- Full Text
- View/download PDF
12. Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial.
- Author
-
UCL - SSS/IREC/GAEN - Pôle d'Hépato-gastro-entérologie, UCL - (SLuc) Service de gastro-entérologie, Merle, Philippe, Blanc, Jean-Frederic, Phelip, Jean-Marc, Pelletier, Gilles, Bronowicki, Jean-Pierre, Touchefeu, Yann, Pageaux, Georges, Gerolami, René, Habersetzer, François, Nguyen-Khac, Eric, Casadei-Gardini, Andrea, Borbath, Ivan, Tran, Albert, Wege, Henning, Saad, Amr Shafik, Colombo, Massimo, Abergel, Armand, Richou, Carine, Waked, Imam, Yee, Nelson S, Molé, Audrey, Attali, Pierre, Le Boulicaut, Julie, Vasseur, Bérangère, RELIVE Investigators, UCL - SSS/IREC/GAEN - Pôle d'Hépato-gastro-entérologie, UCL - (SLuc) Service de gastro-entérologie, Merle, Philippe, Blanc, Jean-Frederic, Phelip, Jean-Marc, Pelletier, Gilles, Bronowicki, Jean-Pierre, Touchefeu, Yann, Pageaux, Georges, Gerolami, René, Habersetzer, François, Nguyen-Khac, Eric, Casadei-Gardini, Andrea, Borbath, Ivan, Tran, Albert, Wege, Henning, Saad, Amr Shafik, Colombo, Massimo, Abergel, Armand, Richou, Carine, Waked, Imam, Yee, Nelson S, Molé, Audrey, Attali, Pierre, Le Boulicaut, Julie, Vasseur, Bérangère, and RELIVE Investigators
- Abstract
BACKGROUND: Cytotoxic chemotherapy is generally ineffective in patients with hepatocellular carcinoma. We assessed the intravenous perfusion of doxorubicin-loaded nanoparticles in patients with hepatocellular carcinoma in whom previous sorafenib therapy had failed. METHODS: We did a multicentre, open-label, randomised, controlled phase 3 trial at 70 sites in 11 countries. Patients with hepatocellular carcinoma with one or more previous systemic therapies, including sorafenib, were randomly assigned to receive 30 mg/m2 doxorubicin-loaded nanoparticles (30 mg/m2 group), 20 mg/m2 doxorubicin-loaded nanoparticles (20 mg/m2 group), or standard care using a computer-generated randomisation list prepared by the funder and stratified by geographic region. Patients in the experimental groups received perfusion of the drug every 4 weeks and those in the control group received any systemic anticancer therapy (except sorafenib) as per investigator decision. The primary endpoint was overall survival in the intention-to-treat population. Safety was assessed in the population of patients who received at least one dose of their assigned treatment. This trial is registered with ClinicalTrials.gov, number NCT01655693. FINDINGS: Between June 15, 2012, and Jan 27, 2017, 541 patients were screened, of whom 144 were excluded and 397 were randomly assigned to one of the groups (133 to the 30 mg/m2 group; 130 to the 20 mg/m2 group; and 134 to the control group). Median follow-up was 22·7 months (IQR 11·2-34·9). After pooling the doxorubicin groups for the efficacy analysis, median overall survival was 9·1 months (95% CI 8·1-10·4) in the pooled doxorubicin-loaded nanoparticles group and 9·0 months (7·1-11·8) in the control group (HR 1·00 [95% CI 0·78-1·28], two-sided p=0·99). 227 (94%) of 242 patients who received doxorubicin-loaded nanoparticles and 100 (75%) of 134 patients in the control group had at least one treatment-emergent adverse event. The most common drug-related grade 3 or 4 tr
- Published
- 2019
13. BRIP1 coding variants are associated with a high risk of hepatocellular carcinoma occurrence in patients with HCV- or HBV-related liver disease
- Author
-
Oussalah, Abderrahim, Avogbe, Patrice Hodonou, Guyot, Erwan, Chery, Céline, Guéant, Rosa-Maria, Ganne-Carrié, Nathalie, Cobat, Aurélie, Moradpour, Darius, Nalpas, Bertrand, Negro, Francesco, Poynard, Thierry, Pol, Stanislas, Bochud, Pierre, Abel, Laurent, Jeulin, Hélène, Schvoerer, Evelyne, Chabi, Nicodème, Amouzou, Emile, Sanni, Ambaliou, Barraud, Hélène, Rouyer, Pierre, Josse, Thomas, Goffinet, Laetitia, Jouve, Jean-Louis, Minello, Anne, Bonithon-Kopp, Claire, Thiefin, Gérard, Di Martino, Vincent, Doffoël, Michel, Richou, Carine, Raab, Jean-Jacques, Hillon, Patrick, Bronowicki, Jean-Pierre, Guéant, Jean-Louis, Nutrition-Génétique et Exposition aux Risques Environnementaux ( NGERE ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université de Lorraine ( UL ), Centre Hospitalier Régional Universitaire de Nancy ( CHRU Nancy ), Université Paris 13 ( UP13 ), Hôpital Jean Verdier [Bondy], Assistance publique - Hôpitaux de Paris (AP-HP), Génomique Fonctionnelle des Tumeurs Solides ( U1162 ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université Paris Descartes - Paris 5 ( UPD5 ) -Université Paris Diderot - Paris 7 ( UPD7 ) -Université Paris 13 ( UP13 ), Université Paris Descartes - Faculté de Médecine ( UPD5 Médecine ), Université Paris Descartes - Paris 5 ( UPD5 ), Imagine - Institut des maladies génétiques ( IMAGINE - U1163 ), Centre National de la Recherche Scientifique ( CNRS ) -Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Université de Lausanne ( UNIL ), Département d'hépatologie [CHU Cochin], Institut Pasteur [Paris]-CHU Cochin [AP-HP]-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Centre d'Hydrogéologie et de Géothermie [Neuchâtel] ( CHYN ), Université de Neuchâtel ( UNINE ), Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Institute of cardiometabolism and nutrition ( ICAN ), Assistance publique - Hôpitaux de Paris (AP-HP)-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -CHU Pitié-Salpêtrière [APHP]-Sorbonne Université, Service d'hépatologie médicale [CHU Cochin], CHU Cochin [AP-HP]-Assistance publique - Hôpitaux de Paris (AP-HP), The Rockefeller University [New-York], Université de Lorraine ( UL ), Laboratoire de Virologie [Strasbourg], Université de Kara, University of Abomey Calavi ( UAC ), Service d'Hépato-gastro-entérologie [CHRU Nancy], Lipides - Nutrition - Cancer [Dijon - U1231] ( LNC ), Université de Bourgogne ( UB ) -AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Centre Hospitalier Universitaire de Reims ( CHU Reims ), Service d'hépatologie, Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Hôpital Jean Minjoz-Université de Franche-Comté ( UFC ), CHU Strasbourg, Hôpital Jean Minjoz, Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ), Centre hospitalier régional Metz-Thionville ( CHR Metz-Thionville ), This study was supported by a French Government grant managed by the French National Research Agency under the program 'Investissements d’Avenir', reference ANR-11-LABX-0021 and also by the Institut National du Cancer (INCA), the French regions of Lorraine and Burgundy, the Ligue Nationale contre le Cancer (CiRCE-Nutrigenex), the European Regional Development Fund, the Canceropole Grand-Est, and the Fondation de France.The ANRS Study HC EP 26 Genoscan group is supported by the National Agency for Research on AIDS and Viral Hepatitis (ANRS).The Swiss Hepatitis C Cohort Study (SCCS) is supported by grants from the Swiss National Science Foundation (3347C0-108782/1), the Swiss Federal Office for Education and Sciences (03.0599) and the European Commission (LSHM-CT-2004-503359, VIRGIL Network of Excellence on Antiviral Drug Resistance). The SCCS genetic project is supported by the Leenaards foundation, the Santos-Suarez foundation and the Swiss National Science Foundation (324730-144054), ANR-11-LABX-0021/11-LABX-0021,Lipstic,Lipoprotéines et santé : prévention et traitement des maladies inflammatoires non vasculaires et du ( 2011 ), Nutrition-Génétique et Exposition aux Risques Environnementaux (NGERE), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Université Paris 13 (UP13), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Génomique Fonctionnelle des Tumeurs Solides (U1162), Université Paris 13 (UP13)-Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Paris Descartes - Faculté de Médecine (UPD5 Médecine), Université Paris Descartes - Paris 5 (UPD5), Imagine - Institut des maladies génétiques (IMAGINE - U1163), Centre National de la Recherche Scientifique (CNRS)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Lausanne (UNIL), CHU Cochin [AP-HP]-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre d'Hydrogéologie et de Géothermie [Neuchâtel] (CHYN), Université de Neuchâtel (UNINE), Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Institute of cardiometabolism and nutrition (ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [APHP]-Sorbonne Université (SU), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Cochin [AP-HP], Rockefeller University [New York], Université de Lorraine (UL), Service de Virologie [CHRU Nancy], Stress, Immunité, Pathogènes (SIMPA), University of Abomey Calavi (UAC), Lipides - Nutrition - Cancer [Dijon - U1231] (LNC), Université de Bourgogne (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement, Centre Hospitalier Universitaire de Reims (CHU Reims), Centre Hospitalier Régional Universitaire [Besançon] (CHRU Besançon)-Hôpital Jean Minjoz-Université de Franche-Comté (UFC), Centre Hospitalier Régional Universitaire [Besançon] (CHRU Besançon), Centre hospitalier régional Metz-Thionville (CHR Metz-Thionville), ANR-11-LABX-0021/11-LABX-0021,Lipstic,Lipoprotéines et santé : prévention et traitement des maladies inflammatoires non vasculaires et du(2011), CiRCE Study Group, Hôpital Jean Verdier, Université Paris 13 ( UP13 ) -Université Paris Diderot - Paris 7 ( UPD7 ) -Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Département d'hépathologie [CHU Cochin], Université de Neuchâtel, Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Cochin [AP-HP], Université d'Abomey Calavi, Hôpital Jean Verdier [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Hôpital Cochin [AP-HP], Laboratoire de Chimie Physique et Microbiologie pour l'Environnement (LCPME), Université de Lorraine (UL)-Centre National de la Recherche Scientifique (CNRS)-Institut de Chimie du CNRS (INC), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), and ANR-11-LABX-0021,Lipstic,Lipoprotéines et santé : prévention et traitement des maladies inflammatoires non vasculaires et du(2011)
- Subjects
hepatitis C virus ,BRIP1 ,DNA repair genes ,hepatitis B virus ,hepatocellular carcinoma ,[SDV.GEN.GH]Life Sciences [q-bio]/Genetics/Human genetics ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology ,[ SDV.MHEP.HEG ] Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology ,[ SDV.GEN.GH ] Life Sciences [q-bio]/Genetics/Human genetics ,Research Paper ,[ SDV.CAN ] Life Sciences [q-bio]/Cancer - Abstract
IF 5.008; International audience; The molecular mechanisms of hepatocellular carcinoma (HCC) carcinogenesis are still not fully understood. DNA repair defects may influence HCC risk. The aim of the study was to look for potential genetic variants of DNA repair genes associated with HCC risk among patients with alcohol- or viral-induced liver disease. We performed four case-control studies on 2,006 European- (Derivation#1 and #2 studies) and African-ancestry (Validation#1 and #2 studies) patients originating from several cohorts in order to assess the association between genetic variants on DNA repair genes and HCC risk using a custom array encompassing 94 genes. In the Derivation#1 study, the BRIP1 locus reached array-wide significance (Chi-squared SV-Perm, P=5.00×10-4) among the 253 haplotype blocks tested for their association with HCC risk, in patients with viral cirrhosis but not among those with alcoholic cirrhosis. The BRIP1 haplotype block included three exonic variants (rs4986763, rs4986764, rs4986765). The BRIP1 'AAA' haplotype was significantly associated with an increased HCC risk [odds ratio (OR), 2.01 (1.19-3.39); false discovery rate (FDR)-P=1.31×10-2]. In the Derivation#2 study, results were confirmed for the BRIP1 'GGG' haplotype [OR, 0.53 (0.36-0.79); FDR-P=3.90×10-3]. In both Validation#1 and #2 studies, BRIP1 'AAA' haplotype was significantly associated with an increased risk of HCC [OR, 1.71 (1.09-2.68); FDR-P=7.30×10-2; and OR, 6.45 (4.17-9.99); FDR-P=2.33×10-19, respectively]. Association between the BRIP1 locus and HCC risk suggests that impaired DNA mismatch repair might play a role in liver carcinogenesis, among patients with HCV- or HBV-related liver disease.
- Published
- 2016
- Full Text
- View/download PDF
14. Increased Incidence and Characteristics of Alveolar Echinococcosis in Patients With Immunosuppression-Associated Conditions
- Author
-
Sondag Daniel, Cusenier Bernadette, Alby-Lepresle Blandine, Delattre Jean Francois, Gerard Alain, Samuel Didier, Farges Olivier, Dominique A. Vuitton, Letranchant Lorraine, Jenny Knapp, Watelet Jérôme, Brientini Marie Pascale, Bresson-Hadni Solange, Guillaud Olivier, Hillon Patrick, Cappelle Sylvie, Piarroux Martine, Debruyne Monique, Vuitton Dominique Angèle, Valmary-Degano Séverine, Godet Claire, Adrien Chauchet, Beytout Jean, Hansmann Yves, Laurence Millon, Besancenot Jean François, Li Véronique, Contreras Remy, Raoul Francis, Vitrat Virginie, Eric Delabrousse, Partensky Christian, Koch Stéphane, Mantion Georges, Evrard Philippe, Delabrousse Eric, Carine Richou, Dumortier Jérôme, Raabe Jean-Jacques, Remy Contreras, Wallon Martine, Beurton-Chataigner Isabelle, Abou-Bacar Ahmed, Di Martino Vincent, Chemla Cathy, Heyd Bruno, Machouart Marie, Audet Maxime, Richou Carine, Oleg Blagosklonov, Vanlemmens Claire, Minello Anne, Bardonnet Karine, Giraudoux Patrick, Felix Sophie, Frédéric Grenouillet, Blagosklonov Oleg, Abergel Armand, Vuitton Lucine, Rabodonirina Meja, Faure Odile, Charlotte Dentan, Guerin Bruno, Grenouillet Frédéric, Knapp Jenny, Lefebvre Nicolas, Johann Marc, Solange Bresson-Hadni, Cambon Monique, Chatelain Eric, Eric Deconinck, Letoublon Christian, Prost Patricia, Bartholomot Brigitte, Vincent Di Martino, Millon Laurence, Service d'hématologie, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Laboratoire Chrono-environnement - CNRS - UBFC (UMR 6249) (LCE), Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), WHO Collaborating Center on Prevention and Treatment of Human Echinococcosis, Université de Franche-Comté (UFC), Service d'hépatologie, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Université de Franche-Comté (UFC), Service de Médecine nucléaire, biophysique, isotopes [CHRU Besançon], Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -hopital Jean Minjoz, Laboratoire Chrono-environnement ( LCE ), Université Bourgogne Franche-Comté ( UBFC ) -Centre National de la Recherche Scientifique ( CNRS ) -Université de Franche-Comté ( UFC ), Hôpital Jean Minjoz, Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ), Université de Franche-Comté ( UFC ), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Hôpital Jean Minjoz-Université de Franche-Comté ( UFC ), Dept. of Nucl. Med., Jean Minjoz Univ. Hosp., Besancon, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), and Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC )
- Subjects
Male ,Microbiology (medical) ,Echinococcosis, Hepatic ,medicine.medical_specialty ,Delayed Diagnosis ,medicine.medical_treatment ,Echinococcus multilocularis ,Risk Assessment ,Gastroenterology ,[ SDV.EE.SANT ] Life Sciences [q-bio]/Ecology, environment/Health ,Albendazole ,Serology ,Immunocompromised Host ,Echinococcosis ,Risk Factors ,Internal medicine ,medicine ,Humans ,Abscess ,Aged ,[SDV.EE.SANT]Life Sciences [q-bio]/Ecology, environment/Health ,biology ,business.industry ,Incidence ,Incidence (epidemiology) ,Immunosuppression ,Middle Aged ,medicine.disease ,biology.organism_classification ,3. Good health ,Surgery ,Infectious Diseases ,Concomitant ,Female ,business ,Liver abscess ,medicine.drug - Abstract
International audience; BACKGROUND: An increased incidence of alveolar echinococcosis (AE) in patients with immunosuppression (IS) has been observed; our aim was to study this association and its characteristics. METHODS: Fifty AE cases with IS-associated conditions (ISCs) before or at AE diagnosis were collected from the French AE registry (1982-2012, 509 cases). There were 30 cancers, 9 malignant hematological disorders, 14 chronic inflammatory diseases, 5 transplants, and 1 case of AIDS; 9 patients had ≥2 ISCs. Characteristics of the 42 IS/AE cases and the 187 non-IS/AE cases diagnosed during the period 2002-2012 were statistically compared. RESULTS: There was a significant increase in IS/AE cases over time. Risk factors did not differ between IS/AE and non-IS/AE patients. However, AE was more frequently an incidental finding (78% vs 42%) and was diagnosed at earlier stages (41% vs 23%) in IS/AE than in non-IS/AE patients. Serology was more often negative (14% vs 1%) and treatment efficacy was better (51% regression after 1-year treatment vs 27%) in IS/AE patients. All IS/AE patients but 7 took IS drugs; 7 received biotherapeutic agents. When not concomitant, AE occurred in IS patients within a 48-month median time period. Atypical presentation and abscess-, hemangioma-, and metastasis-like images delayed AE diagnosis in 50% of IS/AE patients, resulting in inappropriate treatment. Liver images obtained for 15 patients 1-5 years before diagnosis showed no AE lesions. Albendazole efficacy was good, but 19 of 48 treated patients experienced side effects. CONCLUSIONS: Patients with immunosuppression are at increased risk for occurrence, delayed diagnosis, and progression of AE.
- Published
- 2014
- Full Text
- View/download PDF
15. The Role of Delayed 18F-FDG PET Imaging in the Follow-up of Patients with Alveolar Echinococcosis
- Author
-
Caoduro, Cécile, primary, Porot, Clémence, additional, Vuitton, Dominique A., additional, Bresson-Hadni, Solange, additional, Grenouillet, Frédéric, additional, Richou, Carine, additional, Boulahdour, Hatem, additional, and Blagosklonov, Oleg, additional
- Published
- 2013
- Full Text
- View/download PDF
16. Reassessment of the prognosis of hepatocellular carcinoma (HCC): Results of a study in 217 non-selected consecutive patients recently diagnosed
- Author
-
Coron, Emmanuel, primary, Gournay, Jerome, additional, Richou, Carine, additional, Masliah, Claude, additional, Neel, Jean-Claude Le, additional, Hamy, Antoine, additional, Paineau, Jacques, additional, D'Alincourt, Aline, additional, Lerat, Frederic, additional, and Galmiche, Jean-Paul, additional
- Published
- 2003
- Full Text
- View/download PDF
17. The Role of Delayed 18F-FDG PET Imaging in the Follow-up of Patients with Alveolar Echinococcosis.
- Author
-
Caoduro, Cécile, Porot, Clémence, Vuitton, Dominique A., Bresson-Hadni, Solange, Grenouillet, Frédéric, Richou, Carine, Boulahdour, Hatem, and Blagosklonov, Oleg
- Published
- 2013
- Full Text
- View/download PDF
18. Genotyping Echinococcusmultilocularis in Human Alveolar Echinococcosis Patients: An EmsB Microsatellite Analysis.
- Author
-
Knapp, Jenny, Gottstein, Bruno, Bretagne, Stéphane, Bart, Jean-Mathieu, Umhang, Gérald, Richou, Carine, Bresson-Hadni, Solange, and Millon, Laurence
- Subjects
ECHINOCOCCOSIS ,MICROSATELLITE repeats ,INCUBATION period (Communicable diseases) ,GENETIC markers ,CLINICAL epidemiology ,ECHINOCOCCUS multilocularis - Abstract
For clinical epidemiology specialists, connecting the genetic diversity of Echinococcusmultilocularis to sources of infection or particular sites has become somewhat of a holy grail. It is very difficult to trace the infection history of alveolar echinococcosis (AE) patients as there may be an incubation period of five to 15 years before reliable diagnosis. Moreover, the variability of parasitic manifestations in human patients raises the possibility of genetically different isolates of E. multilocularis having different levels of pathogenicity. Thus, the exposure of human patients to different strains or genotypes circulating in geographically different environments may lead to different disease outcomes. Molecular tools, such as the microsatellite marker EmsB, were required to investigate these aspects. This genetic marker was previously tested on a collection of 1211 European field samples predominantly of animal origin, referenced on a publicly available database. In this study, we investigated a panel of 66 metacestode samples (between 1981 and 2019) recovered surgically from 63 patients diagnosed with alveolar echinococcosis originating from four European countries (France, Switzerland, Germany, Belgium). In this study, we identified nine EmsB profiles, five of which were found in patients located in the same areas of France and Switzerland. One profile was detected on both sides of the French-Swiss border, whereas most patients from non-endemic regions clustered together in another profile. EmsB profiles appeared to remain stable over time because similar profiles were detected in patients who underwent surgery recently and patients who underwent surgery some time ago. This study sheds light on possible pathways of contamination in humans, including proximity contamination in some cases, and the dominant contamination profiles in Europe, particularly for extrahepatic lesions. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
19. Genotyping Echinococcus multilocularis in Human Alveolar Echinococcosis Patients: An EmsB Microsatellite Analysis
- Author
-
Knapp, Jenny, Gottstein, Bruno, Bretagne, St��phane, Bart, Jean-Mathieu, Umhang, G��rald, Richou, Carine, Bresson-Hadni, Solange, and Millon, Laurence
- Subjects
570 Life sciences ,biology ,610 Medicine & health ,3. Good health - Abstract
For clinical epidemiology specialists, connecting the genetic diversity of Echinococcus multilocularis to sources of infection or particular sites has become somewhat of a holy grail. It is very difficult to trace the infection history of alveolar echinococcosis (AE) patients as there may be an incubation period of five to 15 years before reliable diagnosis. Moreover, the variability of parasitic manifestations in human patients raises the possibility of genetically different isolates of E. multilocularis having different levels of pathogenicity. Thus, the exposure of human patients to different strains or genotypes circulating in geographically different environments may lead to different disease outcomes. Molecular tools, such as the microsatellite marker EmsB, were required to investigate these aspects. This genetic marker was previously tested on a collection of 1211 European field samples predominantly of animal origin, referenced on a publicly available database. In this study, we investigated a panel of 66 metacestode samples (between 1981 and 2019) recovered surgically from 63 patients diagnosed with alveolar echinococcosis originating from four European countries (France, Switzerland, Germany, Belgium). In this study, we identified nine EmsB profiles, five of which were found in patients located in the same areas of France and Switzerland. One profile was detected on both sides of the French-Swiss border, whereas most patients from non-endemic regions clustered together in another profile. EmsB profiles appeared to remain stable over time because similar profiles were detected in patients who underwent surgery recently and patients who underwent surgery some time ago. This study sheds light on possible pathways of contamination in humans, including proximity contamination in some cases, and the dominant contamination profiles in Europe, particularly for extrahepatic lesions.
20. Fatty acid composition of the erythrocyte membrane and risk of hepatocellular carcinoma in cirrhotic patients.
- Author
-
Mouillot T, Rizk M, Pais de Barros JP, Gilloteau A, Busson A, Bernard-Chabert B, Thiefin G, Barraud H, Bronowicki JP, Richou C, Di Martino V, Doffoel M, Minello A, Latournerie M, Jouve JL, Brondel L, Brindisi MC, Petit JM, Hillon P, and Cottet V
- Subjects
- Aged, Biomarkers blood, Carcinoma, Hepatocellular epidemiology, Case-Control Studies, Female, Humans, Liver Cirrhosis epidemiology, Liver Neoplasms epidemiology, Male, Middle Aged, Odds Ratio, Phospholipids blood, Risk Factors, Carcinoma, Hepatocellular blood, Erythrocyte Membrane chemistry, Fatty Acids blood, Liver Cirrhosis blood, Liver Neoplasms blood
- Abstract
Background: Disturbances in fatty acid (FA) metabolism have been reported in cirrhosis, but the role of FAs in the development of hepatocellular carcinoma (HCC) is still unclear. Biomarkers are a promising means to explore the associations between exogenous intake or endogenous production of FAs and cancer risk., Aim: To estimate the relationship between fatty acid content in erythrocyte membranes and HCC risk in cirrhotic patients METHODS: The "CiRCE" case-control study recruited cirrhotic patients from six French hospitals between 2008 and 2012. Cases were cirrhotic patients with HCC (n = 349); controls were cirrhotic patients without HCC at inclusion (n = 550). FA composition of phospholipids in erythrocyte membranes was determined by high performance gas chromatography. Odds ratios for HCC risk according to FA concentrations were estimated with multivariable logistic regression., Results: HCC patients were older and more often men (P < 0.001). In both groups, saturated FAs represented more than 39% of all FAs in erythrocyte membranes, mono-unsaturated FAs around 14%, and polyunsaturated FAs around 46%. High levels of C15:0 + C17:0, C20:1 n-9, C18:2 n-6 and C20:2 n-6 were associated with higher risk of HCC. The levels of C18:0 and C20:4 n-6 were lower in HCC cases than in controls., Conclusions: The FA composition of erythrocyte membranes differed according to the presence of HCC with higher levels of saturated FAs, linoleic and eicosadienoic acids, and lower levels of stearic and arachidonic acids. These alterations may reflect particular dietary patterns and/or altered FA metabolism. Further investigations are warranted., (© 2020 John Wiley & Sons Ltd.)
- Published
- 2020
- Full Text
- View/download PDF
21. BRIP1 coding variants are associated with a high risk of hepatocellular carcinoma occurrence in patients with HCV- or HBV-related liver disease.
- Author
-
Oussalah A, Avogbe PH, Guyot E, Chery C, Guéant-Rodriguez RM, Ganne-Carrié N, Cobat A, Moradpour D, Nalpas B, Negro F, Poynard T, Pol S, Bochud PY, Abel L, Jeulin H, Schvoerer E, Chabi N, Amouzou E, Sanni A, Barraud H, Rouyer P, Josse T, Goffinet L, Jouve JL, Minello A, Bonithon-Kopp C, Thiefin G, Di Martino V, Doffoël M, Richou C, Raab JJ, Hillon P, Bronowicki JP, and Guéant JL
- Abstract
The molecular mechanisms of hepatocellular carcinoma (HCC) carcinogenesis are still not fully understood. DNA repair defects may influence HCC risk. The aim of the study was to look for potential genetic variants of DNA repair genes associated with HCC risk among patients with alcohol- or viral-induced liver disease. We performed four case-control studies on 2,006 European- (Derivation#1 and #2 studies) and African-ancestry (Validation#1 and #2 studies) patients originating from several cohorts in order to assess the association between genetic variants on DNA repair genes and HCC risk using a custom array encompassing 94 genes. In the Derivation#1 study, the BRIP1 locus reached array-wide significance (Chi-squared SV-Perm, P =5.00×10
-4 ) among the 253 haplotype blocks tested for their association with HCC risk, in patients with viral cirrhosis but not among those with alcoholic cirrhosis. The BRIP1 haplotype block included three exonic variants (rs4986763, rs4986764, rs4986765). The BRIP1 ' AAA ' haplotype was significantly associated with an increased HCC risk [odds ratio (OR), 2.01 (1.19-3.39); false discovery rate (FDR)- P =1.31×10-2 ]. In the Derivation#2 study, results were confirmed for the BRIP1 ' GGG ' haplotype [OR, 0.53 (0.36-0.79); FDR- P =3.90×10-3 ]. In both Validation#1 and #2 studies, BRIP1 ' AAA ' haplotype was significantly associated with an increased risk of HCC [OR, 1.71 (1.09-2.68); FDR- P =7.30×10-2 ; and OR, 6.45 (4.17-9.99); FDR- P =2.33×10-19 , respectively]. Association between the BRIP1 locus and HCC risk suggests that impaired DNA mismatch repair might play a role in liver carcinogenesis, among patients with HCV- or HBV-related liver disease., Competing Interests: CONFLICTS OF INTEREST The authors who have taken part in this study declared that they do not have anything to disclose regarding funding or conflict of interest with respect to this manuscript.- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.